Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: Results from the randomized phase 3 CIMPACT trial

By Warren RB, Lebwohl M, Sofen H, et al
Published July 1, 2021

Key Takeaways

Researchers reported three-year results from the CIMPACT phase 3, certolizumab pegol (CZP), an Fc-free, PEGylated anti-tumor necrosis factor biologic, in moderate to severe plaque psoriasis, randomized controlled trial. CZP 200 mg every other week (Q2W), CZP 400 mg Q2W, etanercept biweekly, or placebo were given to adults in a 3:3:3:1 ratio. CZP- and etanercept-treated PASI 75 responders were re-randomized to CZP 200 mg Q2W, CZP 400 mg Q4W, CZP 400 mg Q2W, or placebo for maintenance treatment at Week 16; PASI 75 non-responders were randomized to an open-label escape CZP 400 mg Q2W arm. Patients receiving blinded treatment who entered the open-label extension (OLE; Weeks 48-144) received CZP 200 mg Q2W. Two hundred sixty-one patients received 200 mg Q2W upon OLE entry. The PASI 75 response was maintained in patients who continued to receive 200 mg Q2W treatment from Weeks 16 to 144 (Week 144: 96.2%). Over a three-year period, the response to CZP was durable. There were no new safety signals discovered.

Read the full article on Journal of the European Academy of Dermatology and Venereology.

Share with emailShare to FacebookShare to LinkedInShare to Twitter